NEW YORK, December 6, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Forest Laboratories Inc. (NYSE: FRX), OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED), EnteroMedics, Inc. (NASDAQ: ETRM), Cadence Pharmaceuticals Inc. (NASDAQ: CADX), and Amarin Corporation plc (NASDAQ: AMRN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Forest Laboratories Inc. Research Report
On December 2, 2013, Forest Laboratories Inc. (Forest Laboratories) announced a proposed offering of $1 billion aggregate principal amount of senior unsecured fixed rate notes due 2021. According to Forest Laboratories, the Company intends to use the net proceeds from the offering of the notes to fund the Company's proposed accelerated share repurchase initiative and the remainder for general corporate purposes, which include potential acquisitions and additional share buybacks. The Company also announced its entry into an amendment to its existing undrawn $750 million revolving credit facility with JPMorgan Chase Bank and other lenders, which aims to amend the definition of Consolidated EBITDA to adjust for certain cost savings for the purposes of calculating Forest Laboratories' leverage ratio and interest coverage ratio. The Company further stated that the restrictive agreements covenant was also amended to allow Forest Laboratories to incur additional indebtedness with lien restrictions that are customary for similarly rated US companies and that are not materially more restrictive than the restrictions in the $750 million credit agreement. The Full Research Report on Forest Laboratories Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
OncoMed Pharmaceuticals, Inc. Research Report
On December 3, 2013, OncoMed Pharmaceuticals, Inc.'s (OncoMed Pharmaceuticals) stock jumped significantly by 97.86%, closing the day at $27.70 per share. The Company's stock increased by 111.61% over the previous three trading days, compared to the Dow Jones Industrial Average which decreased by 1.14% during the same trading period. The Full Research Report on OncoMed Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
EnteroMedics, Inc. Research Report
On December 3, 2013, EnteroMedics, Inc. (EnteroMedics) announced the Company's 18 month efficacy and safety results from its 5 year ReCharge Pivotal Trial of VBLOC®. According to the Company, patients in the VBLOC group (n=117), achieved excess weight loss (EWL) of 25%, or 10% total body weight loss (TBL), compared to 12% EWL or 4% TBL for sham control group patients (n=42). Additionally, the Company stated that the 13% difference in EWL demonstrates statistical superiority over sham control and, in total, 54% of patients in the VBLOC group achieved at least 20% EWL while 41% achieved at least 25% EWL, compared to 26% and 17% respectively, for the sham control group, during the same 18-month period. Commenting on the results, Mark B. Knudson, Ph.D., EnteroMedics' President and CEO stated, "These study results, along with multi-year data from our earlier clinical trials, demonstrate durability of effect and a superior record of safety, underscoring the attractive benefit risk profile of VBLOC Therapy. If approved, VBLOC may help to address the lifelong challenges associated with obesity by offering a treatment option that supports safe, long-term weight loss and a healthy lifestyle." The Full Research Report on EnteroMedics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Cadence Pharmaceuticals Inc. Research Report
On December 3, 2013, Cadence Pharmaceuticals Inc.'s (Cadence Pharmaceuticals) stock was up by 6.15%, at $10.01 per share. The Company's stock went up by 12.09% over the past three trading days, compared to the Nasdaq Composite which went down by 0.19% during the same trading period. The Full Research Report on Cadence Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Amarin Corporation plc Research Report
On December 2, 2013, Amarin Corporation plc (Amarin) announced that the United States Patent and Trademark Office (USPTO) has published notification of Notices of Allowance for the Company's U.S. Patent Applications Serial Numbers 13/685,281, and 13/685,291, each titled "Stable Pharmaceutical Composition and Methods of Using Same." According to the Company, the claims in the allowed applications cover methods of lowering triglycerides by administering a pharmaceutical composition comprised of a mixture of free fatty acids, including EPA and/or DHA to varying degrees, to patients with severe hypertriglyceridemia (the MARINE population) and in patients with hypertriglyceridemia on concomitant statin therapy (the ANCHOR population). Amarin informed that the notice of allowance is issued after the USPTO makes a determination that patent can be granted from an application, and that the issued patents would have terms that expire no earlier than 2030. Amarin also stated that the applications are part of the Company's expanding patent portfolio with 38 patent applications now either issued or allowed with the USPTO and over 30 additional applications pending in the US. The Full Research Report on Amarin Corporation plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner